Search results for: Pricing and Reimbursement
Filter search results
Adaptation to Health States: Sick Yet Better Off?
21 June 2017
…(BCS70) which includes measures of both SAH and changes in the health state of the individuals, and information on the onset of chronic diseases and respondents’ experience of health shocks,…
OHE at the 2019 International Health Economics Association (iHEA) World Congress
5 July 2019
…will unpick the various factors using data on concessionary price increases, trends in Category M and W prices, and interviews with relevant stakeholders. The study explores whether there is a…
How Should the World Pay for a COVID-19 Vaccine?
26 May 2020, 12:00am
…collaboration. Analysis will consider the work of Gavi and others to construct a global vaccine market that delivers for all citizens. Development and administration of a safe and effective vaccine,…
The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’
3 December 2020
…Implementation should be facilitated by funding support and reimbursement of high-value diagnostics tests, including tests in primary care; and The information collected from real-world data should be shared and analysed,…
OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward
21 June 2022
…4 Hamilton Place, an Edwardian Mansion in the heart of Mayfair, London. About 140 attendants were served nibbles and drinks on the terrace with views over Hyde Park and listened…
Health Care Services and the Single European Market
1 September 2008
…health systems are compatible; the potential impact of increased competition on efficiency, quality and access to health services and the effect of relying on patient choice to promote competition; and…
Productivity Costs: Principles and Practice in Economic Evaluation
11 January 2000
…are the human capital approach, the friction cost approach and the approach recommended by the US Panel on Cost-Effectiveness in Health and Medicine. The friction cost approach responds to concerns…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
…evolved since 2009 in France, Germany, Italy, Sweden and the UK. The author highlights two key results. Firstly, the market experience varies greatly across product classes and countries – mainly…
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
5 January 2020
…these countries, this review examines whether an explicit or implicit CET is used, and the additional considerations (here termed ‘modifiers’) that are incorporated when funding and reimbursement decisions are made….